Safety of hyperbaric oxygen therapy in patients with heart

failure: A retrospective review

- 4 Simone Schiavo 1,2, Connor T. A. Brenna 1, Lisa Albertini 3, George Djaiani 1,2,
- 5 Anton Marinov 1,4, Rita Katznelson 1,2,4
- 7 Department of Anesthesiology & Pain Medicine, University of Toronto, Toronto, ON, Canada
- 8 ² Hyperbaric Medicine Unit, Toronto General Hospital, Toronto, ON, Canada;
- 9 <u>hyperbaricmedicineunit@uhn.ca</u> Department of Anesthesia and Pain Management, University Health Network,
- 10 Toronto, ON, Canada

3

6

- 11 ³ Department of Medicine, Division of Cardiology, University of Toronto, Toronto, ON, Canada
- 12 ⁴Rouge Valley Hyperbaric Medical Center, Scarborough, ON, Canada
- 14 Corresponding author: Rita Katznelson, rita.katznelson@uhn.ca

Abstract

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

Background: Hyperbaric oxygen therapy (HBOT) has several hemodynamic effects including increases in afterload (due to vasoconstriction) and decreases in cardiac output. This, along with rare reports of pulmonary edema during emergency treatment, has led providers to consider HBOT relatively contraindicated in patients with reduced left ventricular ejection fraction (LVEF). However, there is limited evidence regarding the safety of elective HBOT in patients with heart failure (HF), and no existing reports of complications among patients with HF and preserved LVEF. We aimed to retrospectively review patients with preexisting diagnoses of HF who underwent elective HBOT, to analyze HBOT-related acute HF complications. Methods: Research Ethics Board approvals were received to retrospectively review patient charts. Patients with a history of HF with either preserved ejection fraction (HFpEF), mid-range ejection fraction (HFmEF), or reduced ejection fraction (HFrEF) who underwent elective HBOT at two Hyperbaric Centers (Toronto General Hospital, Rouge Valley Hyperbaric Medical Centre) between June 2018 and December 2020 were reviewed. Results: Twenty-three patients with a history of HF underwent HBOT, completing an average of 39 (range 6 – 62) consecutive sessions at 2.0 atmospheres absolute (ATA) (n=11) or at 2.4 ATA (n=12); only two patients received fewer than 10 sessions. Thirteen patients had HFpEF (mean LVEF 55 ± 7%), and seven patients had HFrEF (mean LVEF 35 ± 8%) as well as concomitantly decreased right ventricle function (n=5), moderate/severe tricuspid regurgitation (n=3), or pulmonary hypertension (n=5). The remaining three patients had HFmEF (mean LVEF $44 \pm 4\%$). All but one patient was receiving fluid balance therapy either with loop diuretics or dialysis.

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

Twenty-one patients completed HBOT without complications. We observed symptoms consistent with HBOT-related HF exacerbation in two patients. One patient with HFrEF (LVEF 24%) developed dyspnea attributed to pulmonary edema after the fourth treatment, and later admitted to voluntarily holding his diuretics before the session. He was managed with increased oral diuretics as an outpatient, and ultimately completed a course of 33 HBOT sessions uneventfully. Another patient with HFpEF (LVEF 64%) developed dyspnea and desaturation after six sessions, requiring hospital admission. Acute coronary ischemia and pulmonary embolism were ruled out, and an elevated BNP and normal LVEF on echocardiogram confirmed a diagnosis of pulmonary edema in the context of HFpEF. Symptoms subsided after diuretic treatment and the patient was discharged home in stable condition, but elected not to resume HBOT. Conclusions: Patients with HF, including HFpEF, may develop HF symptoms during HBOT and warrant ongoing surveillance. However, these patients can receive HBOT safely after optimization of HF therapy and fluid restriction.

Introduction

Hyperbaric oxygen therapy (HBOT) is an evidence-based intervention used to treat a variety of elective conditions, in addition to its role as an emergency treatment for carbon monoxide toxicity, decompression sickness, and arterial gas embolism (S1 Table) (1). The safety profile of HBOT is very favorable: although minor side effects related to increased environmental pressure and/or systemic hyperoxia can occur (e.g., claustrophobia, transient myopia, or middle ear barotrauma) (2-4), serious treatment complications (e.g., seizures, pulmonary oxygen toxicity, or pulmonary edema) are extremely rare (5). Anectodical evidence has suggested that patients with decreased left ventricular ejection fraction (LVEF) may be at an increased risk of acute heart failure (HF) during HBOT (6). Although this risk has not been substantiated by robust evidence, left ventricular (LV) systolic dysfunction has traditionally been considered a relative contraindication to HBOT (6).

Several hemodynamic changes are known to occur during and immediately after hyperbaric oxygen exposure (7). HBOT increases cardiovascular afterload, with associated increases in systolic and mean arterial blood pressure (BP), while cardiac output (CO) decreases due primarily to a decrease in heart rate (HR). Previous literature characterizing the effect of HBOT on CO is summarized in Table 1.

Table 1. Previous studies characterizing the effect of hyperbaric oxygen therapy on cardiac output.

Study	CO change	ATA
	_	

	(% compared to baseline)	
Whalen, 1965 (8)	-13	3.04
Pisarello, 1987 (9)	-8	3.0
	-15	2.5
Pelaia, 1992 (10)	-17	2.2
McMahon, 2002 (11)	-10	3.0
Weaver, 2009 (12)	-18	2.5
	-16	3.0

- 71 Changes in cardiac output associated with hyperbaric oxygen therapy among previous reports.
 - Abbreviations: CO = cardiac output, ATA = absolute atmospheres of pressure.

Numerous mechanisms for the effect of HBOT on CO have been suggested (13, 14) although this effect predominately results from HBOT-induced vasoconstriction, the physiological protective response to extremely high arterial partial pressures of oxygen (7). These hemodynamic changes appear to be well tolerated in patients without preexisting cardiac disease (15, 16). However, there is limited evidence regarding the applicability of HBOT in patients with HF and reduced ejection fraction (HFrEF) and, furthermore, no data on patients with HF with preserved ejection fraction (HFpEF) or HF with mid-range ejection fraction (HFmEF). We aimed to examine the safety of HBOT for patients with preexisting diagnoses of HF.

Methods

Study design

This is a retrospective longitudinal cohort study of patients with HF who underwent elective HBOT between June 2018 and December 2020 in two Hyperbaric Medicine Centers in Ontario, Canada (Toronto General Hospital, Toronto; Rouge Valley Hyperbaric Medical Centre, Scarborough). Institutional Research Ethics Board approvals (CAPCR ID: 19-5081.1; IRB ID:2023-3194-14092-4) were obtained for study team members to collect data from medical records (last access to data on March 31, 2023; all authors but one (SS) did not have access to information that could identify individual participants during or after data collection).

Definitions

In accordance with the Canadian Cardiovascular society guidelines (17), HF was defined as a clinical syndrome in which abnormal heart function results in (or increases the risk of) clinical symptoms and signs of reduced cardiac output and/or pulmonary or systemic congestion either at rest or with stress. Chronic HF represents the persistent and progressive nature of the disease, whereas acute HF is defined as a change in HF signs and symptoms resulting in the need for urgent therapy. Recent guidelines proposed a new and revised classification of HF according to LVEF (18-20), which includes: (i) HF with preserved ejection fraction (HFpEF) = LVEF \geq 50%; (ii) HF with mid-range ejection fraction (HFmEF) = LVEF 41-49%; and (iii) HF with reduced ejection fraction (HFrEF) = LVEF \leq 40%.

HFpEF is diagnosed in patients with signs and symptoms of HF as the result of high LV filling pressure, despite preserved LVEF (≥ 50%) (18). These patients also display normal LV volumes and an abnormal diastolic filling pattern (diastolic dysfunction) (18, 21); therefore, HFpEF is sometimes referred to as diastolic heart failure (22, 23).

Participants and data collection

We included all patients 18 years of age or older with a history of HF, regardless of EF, undergoing elective HBOT during the study period. To further categorize these patients, LVEF measurements via echocardiography were identified (where available) and used to stratify patients into three groups: (i) HFpEF = LVEF \geq 50%; (ii) HFmEF = LVEF 41 – 49%; and (iii) HFrEF = LVEF \leq 40% (17).

Each patient's demographic variables, past medical history, and medications were extracted from medical charts. Additional data extracted during the treatment period included HBOT indication, treatment pressure, total number of HBOT sessions, and adverse events associated with HBOT, including subjective symptoms reported by the patients and reported into the medical chart. All patients described in the study provided written consent to undergo HBOT for a clinical indication approved by Health Canada.

Hyperbaric oxygen therapy protocol

Conventional HBOT protocols were utilized in the treatment of all patients, as previously described (15): these included the administration of 100% oxygen at 2.0 or 2.4 atmospheres

absolute (ATA) for 90 minutes, with 1-2 air breaks (0.21 fraction of inspired O_2 at the same ATA) per session, five times weekly, either in a mono-place chambers (Sechrist 3600H and Sechrist 4100H, Sechrist Industries Inc., Anaheim, CA, USA; PAH-S1-3200, Pan-America Hyperbarics Inc., Plano, TX, USA; Sigma 36, Perry Baromedical, Riviera Beach, Fl, USA) or through a plastic hood in the multi-place chamber (rectangular Hyperbaric System, Fink Engineering PTY-LTD, Warana, Australia). Standard monitoring included measurements of systolic (SAP), diastolic (DAP), and mean (MAP) blood pressure (BP), heart rate (HR), and peripheral oxygen saturation (SpO2) assessed during a five-minute period preceding and following each HBOT session. BP was measured non-invasively using an upper arm cuff and automated sphygmomanometer (Connex VSM 6000, WelchAllyn—Hill-Rom, New York, NY, USA) with the patient in a sitting or semi-sitting position.

Outcomes

The objective of this study was to evaluate the safety of HBOT among patients with known HF. The primary outcome was to describe any clinical signs or symptoms of acute heart failure occurring during and immediately after HBOT. Secondary outcomes included other treatment complications, assessed as the number of patients experiencing HBOT-related adverse or serious adverse events, such as barotrauma, oxygen toxicity (either central nervous system or pulmonary), ocular changes, or confinement anxiety.

Statistical analysis

Qualitative data including patient demographics and past medical history characteristics were summarized using descriptive statistics. Continuous data were expressed as means \pm standard deviations.

Results

148

149

150

151

152

Clinical data

During the study period, 23 patients with a documented diagnosis of HF received elective

HBOT. Table 2 summarizes patients' details and HBOT characteristics.

Table 2. Baseline demographics, comorbidities, and medications of the patient cohort.

n= 23 Age (years) 70 ± 12 Body Mass Index (kg/m²) 31 ± 11 Female 8 Comorbidities History of hypertension 21 Baseline Heart Failure classification: 13 Preserved EF (LVEF ≥ 50%) Mid-range EF (LVEF ≤ 40%) 3 Reduced EF (LVEF ≤ 40%) 7 Coronary artery disease 14 Left ventricular hypertrophy 7 Heart valvular disease 6 Diastolic dysfunction 7 Atrial fibrillation 9 Peripheral vascular disease 11 Diabetes mellitus: 2 Type 1 2 Type 2 16 Chronic obstructive pulmonary disease 5 Restrictive lung disease 0 Smoking status: 15 Renal insufficiency 14 Dialysis 5 Medications ACEi/ARBs 11 B-blockers 13 Calcium channel blockers 13 Diuretics 18 <t< th=""><th></th><th></th></t<>		
Body Mass Index (kg/m²) 31 ± 11 Female8Comorbidities13History of hypertension 21 Baseline Heart Failure classification: 13 Preserved EF (LVEF ≥ 50%) Mid-range EF (LVEF 41-49%) Reduced EF (LVEF 44-49%)Reduced EF (LVEF 44-49%) 7 Reduced EF (LVEF ≤ 40%) 7 Coronary artery disease 14 Left ventricular hypertrophy 7 Heart valvular disease 6 Diastolic dysfunction 7 Atrial fibrillation 9 Peripheral vascular disease 11 Diabetes mellitus: 11 Type 1 Type 2 2 16Chronic obstructive pulmonary disease 5 Restrictive lung disease 0 Smoking status: 15 Never Current Past 15 Renal insufficiency 14 Dialysis 5 Medications 11 ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6		n= 23
Female 8 Comorbidities History of hypertension 21 Baseline Heart Failure classification: 13 Preserved EF (LVEF ≥ 50%) Mid-range EF (LVEF ≤ 40%) 3 Coronary artery disease 14 Left ventricular hypertrophy 7 Heart valvular disease 6 Diastolic dysfunction 7 Atrial fibrillation 9 Peripheral vascular disease 11 Diabetes mellitus: 2 Type 1 2 Type 2 16 Chronic obstructive pulmonary disease 5 Restrictive lung disease 0 Smoking status: 15 Current Post 15 Post 6 Renal insufficiency 14 Dialysis 5 Medications 1 ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	Age (years)	70 ± 12
Female 8 Comorbidities History of hypertension 21 Baseline Heart Failure classification: 13 Preserved EF (LVEF ≥ 50%) Mid-range EF (LVEF ≤ 40%) 3 Coronary artery disease 14 Left ventricular hypertrophy 7 Heart valvular disease 6 Diastolic dysfunction 7 Atrial fibrillation 9 Peripheral vascular disease 11 Diabetes mellitus: 2 Type 1 2 Type 2 16 Chronic obstructive pulmonary disease 5 Restrictive lung disease 0 Smoking status: 15 Current Post 15 Post 6 Renal insufficiency 14 Dialysis 5 Medications 1 ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	Body Mass Index (kg/m²)	31 ± 11
History of hypertension 21 Baseline Heart Failure classification: 13 Preserved EF (LVEF ≥ 50%) 3 Mid-range EF (LVEF 41-49%) 7 Coronary artery disease 14 Left ventricular hypertrophy 7 Heart valvular disease 6 Diastolic dysfunction 7 Atrial fibrillation 9 Peripheral vascular disease 11 Diabetes mellitus: 2 Type 1 Type 2 Tope 2 Chronic obstructive pulmonary disease 5 Restrictive lung disease 0 Smoking status: 15 Renal insufficiency 14 Dialysis 5 Medications ACEI/ARBS 11 B-blockers 15 Calcium channel blockers 13 Diuretics 12		8
Baseline Heart Failure classification: Preserved EF (LVEF ≥ 50%) 3 3 3 3 3 3 3 3 3	Comorbidities	
Baseline Heart Failure classification: Preserved EF (LVEF ≥ 50%) 3 3 3 3 3 3 3 3 3	History of hypertension	21
Preserved EF (LVEF ≥ 50%) Mid-range EF (LVEF 41-49%) Reduced EF (LVEF ≤ 40%) Coronary artery disease Left ventricular hypertrophy Ty Heart valvular disease Diastolic dysfunction 7 Atrial fibrillation Peripheral vascular disease Diabetes mellitus: Type 1 2 Type 1 16 Chronic obstructive pulmonary disease Smoking status: Never Current 15 Past 2 6 6 Renal insufficiency 14 Dialysis 5 Medications ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	,	
Preserved EF (LVEF ≥ 50%) Mid-range EF (LVEF 41-49%) Reduced EF (LVEF ≤ 40%) 3 Coronary artery disease Left ventricular hypertrophy 14 Heart valvular disease 6 Diastolic dysfunction 7 Atrial fibrillation 9 Peripheral vascular disease 11 Diabetes mellitus: 2 Type 1 Type 2 2 Chronic obstructive pulmonary disease 5 Restrictive lung disease 0 Smoking status: 15 Never Current Past 15 Renal insufficiency 14 Dialysis 5 Medications 11 ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	Baseline Heart Failure classification:	13
Mid-range EF (LVEF 41-49%) Reduced EF (LVEF ≤ 40%)Coronary artery disease14Left ventricular hypertrophy7Heart valvular disease6Diastolic dysfunction7Atrial fibrillation9Peripheral vascular disease11Diabetes mellitus:2Type 1 Type 22Chronic obstructive pulmonary disease5Restrictive lung disease0Smoking status:15Current Past2Current Past2Dialysis5Medications14ACEi/ARBs11B-blockers15Calcium channel blockers13Diuretics18Vasodilators6	Preserved EF (LVEF ≥ 50%)	
Coronary artery disease Left ventricular hypertrophy Heart valvular disease Diastolic dysfunction Atrial fibrillation Peripheral vascular disease Diabetes mellitus: Type 1 Type 2 16 Chronic obstructive pulmonary disease Smoking status: Never Current Past Renal insufficiency Dialysis ACEi/ARBS B-blockers Calcium channel blockers Diuretics 14 14 15 16 17 18 19 19 10 10 11 11 12 12 13 14 15 15 16 11 11 11 12 12 13 14 15 15 16 17 18 19 10 10 11 11 12 12		
Left ventricular hypertrophy Heart valvular disease Diastolic dysfunction Atrial fibrillation Peripheral vascular disease Diabetes mellitus: Type 1 Type 2 16 Chronic obstructive pulmonary disease Restrictive lung disease Smoking status: Never Current Past 6 Renal insufficiency Dialysis 5 Medications ACEi/ARBs B-blockers Calcium channel blockers Diuretics Vasodilators 6	Reduced EF (LVEF ≤ 40%)	/
Left ventricular hypertrophy Heart valvular disease Diastolic dysfunction Atrial fibrillation Peripheral vascular disease Diabetes mellitus: Type 1 Type 2 16 Chronic obstructive pulmonary disease Restrictive lung disease Smoking status: Never Current Past 6 Renal insufficiency Dialysis 5 Medications ACEi/ARBs B-blockers Calcium channel blockers Diuretics Vasodilators 6	Coronany arteny disease	
Heart valvular disease Diastolic dysfunction Atrial fibrillation Peripheral vascular disease Diabetes mellitus: Type 1 Type 2 16 Chronic obstructive pulmonary disease Restrictive lung disease Smoking status: Never Current Past 6 Renal insufficiency Dialysis 5 Medications ACEi/ARBs B-blockers Calcium channel blockers Diuretics 12 13 14 15 16 16 17 18 19 10 10 11 11 12 12 13 14 15 15 16 17 18 19 10 10 11 11 12 12 13 14 15 15 16 17 18 19 10 10 11 11 12 12	•	
Diastolic dysfunction 7 Atrial fibrillation 9 Peripheral vascular disease 11 Diabetes mellitus: 2 Type 1 Type 2 16 Chronic obstructive pulmonary disease 5 Restrictive lung disease 0 Smoking status: 15 Current Past 6 Renal insufficiency 14 Dialysis 5 Medications ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	**	•
Atrial fibrillation 9 Peripheral vascular disease 11 Diabetes mellitus: Type 1 Type 2 16 Chronic obstructive pulmonary disease 5 Restrictive lung disease 00 Smoking status: Never Current Past 6 Renal insufficiency 14 Dialysis 5 Medications ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6		
Peripheral vascular disease Diabetes mellitus: Type 1 Type 2 16 Chronic obstructive pulmonary disease Restrictive lung disease Smoking status: Never Current Past 6 Renal insufficiency Dialysis Medications ACEi/ARBs B-blockers Calcium channel blockers Diuretics Vasodilators 11 12	•	•
Diabetes mellitus: Type 1 Type 2 16 Chronic obstructive pulmonary disease Restrictive lung disease Smoking status: Never Current Past 6 Renal insufficiency Dialysis ACEi/ARBs ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 11 Diuretics 12 13 14 15 16 17 18 19 10 10 11 11 12		9
Type 1 2 Type 2 16 Chronic obstructive pulmonary disease 5 Restrictive lung disease 0 Smoking status: Never 15 Current 2 Past 6 Renal insufficiency 14 Dialysis 5 Medications ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	•	11
Type 2 Chronic obstructive pulmonary disease Restrictive lung disease Smoking status: Never		
Chronic obstructive pulmonary disease 5 Restrictive lung disease 0 Smoking status: Never	7.	2
Restrictive lung disease 0 Smoking status: 15 Current Past 2 Renal insufficiency 14 Dialysis 5 Medications ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	Type 2	16
Smoking status: 15 Never Current Past 2 6 6 Renal insufficiency Dialysis 14 Dialysis 5 Medications ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	Chronic obstructive pulmonary disease	5
Never Current Past 15 Renal insufficiency Dialysis 14 Medications 5 ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	Restrictive lung disease	0
Current Past 2 6 6 Renal insufficiency Dialysis 14 Dialysis 5 Medications ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	Smoking status:	
Past 2 6 6 Renal insufficiency 14 Dialysis 5 Medications 1 ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	Never	15
Renal insufficiency 14 Dialysis 5 Medications ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6		2
Renal insufficiency Dialysis 5 Medications ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	Past	
Dialysis 5 Medications ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	Renal insufficiency	<u>-</u>
Medications ACEi/ARBs 11 B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	•	
B-blockers 15 Calcium channel blockers 13 Diuretics 18 Vasodilators 6	·	
Calcium channel blockers 13 Diuretics 18 Vasodilators 6	ACEi/ARBs	11
Calcium channel blockers 13 Diuretics 18 Vasodilators 6	•	
Diuretics 18 Vasodilators 6	Calcium channel blockers	
Vasodilators 6		 -
12		
HBOT Pressure (2.4 ATA)	. 2222	-
	HBOT Pressure (2.4 ATA)	12

Descriptive analysis of patients included in this study (n = 23). Abbreviations: EF = ejection fraction, LVEF = left ventricular ejection fraction, ACEi = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker, ATA = absolute atmospheres of pressure.

The mean patient age was 70 \pm 12 years and 15 (65%) were male. A majority of patients had comorbid diagnoses of hypertension (21; 91%), type 2 diabetes (16; 70%), and/or coronary artery disease (14; 61%). At baseline, 13 (57%), 3 (13%), and 7 (30%) patients had HF categorized as HFpEF (\geq 50%), HFmEF (\pm 40%) and HFrEF (\pm 40%), respectively. All 10 patients with HFrEF or HFmEF (100%) had a prior hospitalization for HF, compared to 7 out of 13 (54%) of patients with HFpEF. Overall, 11 (48%) were receiving treatment with ACEi/ARBs, 15 (65%) with betablockers, and 18 (78%) with diuretics, including 16 with loop diuretics, one with thiazide diuretics and one with potassium-sparing diuretics. Five (22%) patients were on dialysis, including one concurrently receiving diuretics, and only one patient with HFpEF was not receiving any diuretic nor dialysis. Pre-HBOT, all but one patient underwent a transthoracic echocardiography (Table 2) in addition to a clinical assessment which excluded signs of acute heart failure prior to compression.

HBOT characteristics

Twelve patients received HBOT at a pressure of 2.4 ATA; the remaining 11 patients underwent treatment at 2.0 ATA. Collectively, the 23 patients described in this study completed a total of 906 HBOT sessions. Each patient underwent an average of 39 ± 17 treatments, and half

of them (434; 48%) were delivered at 2.4 ATA. Table 3 summarizes details of treatment for each 174 patient.

Table 3. Hyperbaric oxygen therapy details.

175

Patient #	LVEF (%)	ATA	Total number of	Indication
		prescribed	treatments	
1	34	2.4	26	AI LL
2	54	2.4	60	DFU
3	66	2.4	35	AI LL
4	33	2.4	35	STRI-RC
5	55	2.4	23	ORN (jaw)
6	50	2.4	58	DFU
7	52	2.4	50	DFU
8	45	2.4	40	AI LL
9	31	2.0	49	DFU
10	50	2.4	60	СРНҮХ
11	24	2.4	33 *	СРНҮХ
12	64	2.4	6	DFU
13	40	2.4	8	СРНҮХ
14	52	2.0	50	DFU
15	56	2.0	60	DFU
16	48	2.0	42	DFU
17	32	2.0	30	DFU
18	51	2.0	62	DFU
19	30	2.0	17	DFU
20	50	2.0	36	DFU
21		2.0	60	STRI-RP
22	50	2.0	41	СРНҮХ
23	52	2.0	25	DFU

Treatment details for each patient included in the cohort (n = 23), including LVEF, HBOT exposure pressure, number of sessions, indications for HBOT, and treatment center.

Abbreviations: HBOT = hyperbaric oxygen therapy; ATA = absolute atmospheres of pressure;

LVEF = left ventricle ejection fraction; AI LL = arterial insufficiency – lower extremity; DFU = diabetic foot ulcer; STRI = soft tissue radiation injury; RC = radiation cystitis; RP = radiation proctitis; ORN = osteoradionecrosis; CPHYX = calciphylaxis. *Patient #11: 7 out of the 33 sessions were at 2.0 ATA, and the remainder at 2.4 ATA.

Acute cardiovascular complications

We observed symptoms consistent with HBOT-related HF in two patients (2/23, 9%). One patient with HFrEF (LVEF 24%) developed dyspnea after their fourth treatment for a diabetic foot ulcer. He had a history of hypertension, non-ischemic dilated cardiomyopathy, left ventricle hypertrophy, moderate pulmonary hypertension, mild tricuspid regurgitation, moderate diastolic disfunction, atrial fibrillation, peripheral vascular disease, obesity, diabetes, and kidney failure (not on dialysis). A routine random B-type Natriuretic peptide (BNP) collected one month before HBOT was 402 g/mL (Lab reference range: <= 99.9 pg/mL). Following HBOT, examination revealed an increased work of breathing and crackles consistent with pulmonary edema, without peripheral oxygen desaturation. In the emergency department, his BNP was measured at 1580 pg/ml, and he was managed with increased oral diuretics but did not require hospitalization. This patient later disclosed that he had voluntarily held his diuretics before the treatment to avoid

needing to urinate while inside the hyperbaric chamber. He subsequently continued HBOT, completing a total of 33 sessions without further complication.

A second patient, with HFpEF (LVEF 74%), developed dyspnea and desaturation after the sixth treatment session (also for a diabetic foot ulcer), ultimately requiring hospital admission. He had a history of hypertension, type 2 diabetes on insulin, obesity, coronary artery disease with HFpEF, and mild diastolic dysfunction (on double diuretic therapy). His hypertension was reported as well controlled on dual therapy (nifedipine and telmisartan), but a review of his BP measured before and after each session revealed a consistently increased SAP (mean 155 ± 11 mmHg) and normal DAP (77 ± 4 mmHg) before each treatment, and both an increased SAP (170 ± 3 mmHg) and DAP (86 ± 10 mmHg) following each treatment. During the acute episode following his sixth HBOT session, acute coronary ischemia and pulmonary embolism were clinically excluded. A diagnosis of pulmonary edema in the context of HFpEF was made on the basis of an elevated BNP (143 pg/mL), pulmonary congestion identified through bedside lung ultrasound and chest X-ray, and normal LVEF with the presence of diastolic dysfunction on transthoracic echocardiogram. The patient's symptoms subsided after administration of an intravenous loop diuretic (furosemide), and he was discharged home in stable condition. However, he elected not to resume HBOT. Three years later, he died of an unrelated oncologic pathology.

No acute cardiovascular complications were observed among the other 21 patients.

Other complications

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

A total of seven non-serious adverse events were recorded: five instances of middle-ear barotrauma, and two of confinement anxiety. In each case, appropriate coaching and treatment were provided, and all patients continued HBOT without further complication.

Discussion

In this study we investigated whether patients with a history of HF can safely receive HBOT. Two patients in our cohort (9%) experienced acute symptoms of heart failure in relation to HBOT. One had a history of HFrEF, which portends a theoretical risk with respect to HBOT. The other had a history of HFpEF, which has not been previously reported to increase cardiac risks of HBOT.

Heart failure with reduced ejection fraction

HBOT is known to negatively impact cardiac output (CO), even among healthy patients (24). The decreased CO, along with an increased afterload resulting from systemic vascular resistance, has been hypothesized to be the cause of pulmonary edema reported in patients with reduced EF (6). In our cohort, among seven patients with HFrEF, only one developed signs of acute heart failure following HBOT. This patient had a severely impaired LVEF below 30% and he was receiving treatment with loop diuretics, although for two days he had been withholding his morning doses. With appropriate coaching and therapy optimization (an increase in the dose of

his loop diuretic), he continued HBOT and was able to complete 29 additional sessions without further complication. Our experience with these seven patients indicates that HBOT may exacerbate pulmonary congestion in patients with reduced ejection fraction, but also supports the feasibility of cautious treatment with close monitoring in this population after optimization of diuretic therapy. Interestingly, more recent studies have analyzed the long-term effects of HBOT on myocardial function, and paradoxically support a possible positive effect of HBOT on LVEF and other echocardiographic measures over longer time horizons (25-27).

Heart failure with preserved ejection fraction

One of the 13 patients with HFpEF in our cohort developed acute signs of heart failure after six HBOT sessions. He had a history of hypertension, previous admission for heart failure, echocardiographic evidence of diastolic dysfunction, and ongoing treatment with thiazide diuretics but not loop diuretics. His consistently increased SAP and DAP post-sessions may suggest a marked increase in afterload during and after each session (15), and increased afterload is a well-known effect of HBOT which contributes to decreases in CO (6, 12). Further, there is evidence that hyperoxia increases LV end-diastolic pressure (LVEDP), and it is associated with disturbances of both early and late phases of LV filling in patients with and without HF (28). As a result, it is possible that a combination of increased afterload and impaired ventricular relaxation in the context of preexisting diastolic disfunction might represent the mechanism of the pulmonary congestion exacerbation in this patient.

Complications of HFpEF resulting from HBOT have not been previously reported, although this finding is important as HFpEF is more prevalent among older adults, women, and those with obesity, systemic arterial hypertension, diabetes mellitus, and renal dysfunction (29). Given the aging population and the increased medical complexity of patients seen in modern hyperbaric centres, the authors expect an increasing frequency of HBOT candidates with HFpEF in the hyperbaric medicine setting.

Clinical implications

Our data suggest that a minority of patients with HF, regardless of EF, may develop acute heart failure symptoms. However, we also show that this event is rare and potentially preventable, and that these patients can complete HBOT safely after therapy optimization, with close surveillance before and after each session. Cardiac guidelines recommend the use of loop diuretics in patients with HFpEF and HFrEF, aiming to reduce symptoms of congestion (18, 20). In our study, no complications were observed among 21 patients out of 23. Interestingly, all but one of these patients were either on therapy with loop diuretics or receiving regular dialysis. It is possible that optimizing medical therapy (e.g., initiating or titrating loop diuretics) for patients with HFpEF may avoid or further limit pulmonary congestion in the setting of HBOT.

Some HF patients may present for HBOT without the typical history of HF symptoms and low LVEF, well known to physicians as pathognomonic of HFrEF. Indeed, HFpEF is diagnostically challenging for a clinician, given the frequency of atypical symptoms and/or an unremarkable LVEF. In our study, 54% of patients with HFpEF did not have a prior hospitalization primarily

caused by their HF, and the diagnosis was based on transthoracic echocardiogram and signs and/or symptoms of HF while undergoing investigations for other indications (e.g., acute coronary syndrome, or additional tests required during dialysis or diabetes management).

Therefore, even in the absence of a known impairment in LVEF, particular attention to any changes in the patient's clinical condition and pharmacological management during HBOT is warranted, and even mild-to-moderate respiratory or cardiac symptoms during HBOT should trigger further investigation to rule out an acute or subacute episode of HF. Patients with multiple comorbidities treated with numerous medications should be aware that any changes in their medications during HBOT should be discussed with their hyperbaric physician.

For the same reason, the availability of a baseline echocardiogram to facilitate evaluation of diastolic dysfunction during the initial assessment, rather than relying on other tests traditionally performed prior to HBOT (e.g., electrocardiogram or chest x-ray), may further reduce the risk of patients with unrecognized HF developing symptoms in the context of HBOT. However, there is currently a paucity of evidence to define the feasibility or cost-effectiveness of routine cardiac screening before HBOT to prevent these complications.

Finally, both patients who experienced HBOT-related HF in our study developed symptoms after several treatment sessions, rather than after the first one, suggesting the possibility of a cumulative effect of HBOT on pulmonary congestion (rather than acute onset, severe pulmonary edema in a patient who is incidentally referred for HBOT on the brink of this complication). This observation warrants particular consideration in the care of HF patients undergoing HBOT: despite undergoing several uneventful treatment sessions, these patients may

gradually worsen, and still require close surveillance for the entire duration of treatment. Further research is needed to characterize the optimal management of patients with HF undergoing HBOT.

Limitations

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

Our retrospective study has several inherent limitations. Because we retrospectively reviewed health records already compiled at the time of HBOT, it is possible that not all pertinent risk factors were identified and recorded. Our data relate to a cohort of patients treated in two urban centres, potentially limiting their generalizability to other settings; similarly, patients were treated by several different healthcare professionals at these settings, limiting consistency in measurement and reporting. Importantly, our study design cannot appreciate patients with HF who may have been referred for HBOT, assessed, and considered to be at too great a risk to proceed with treatment. Additionally, due to the rarity of patients with HF undergoing HBOT, we report on a small sample size, limiting estimates of the incidence of HF exacerbation related to HBOT, and subgroup analyses (e.g., stratified by EF %) present data on even smaller groups of patients. Finally, the primary outcome of the study was observational, and while two patients experienced symptoms of acute HF following HBOT with a close temporal relationship this cannot prove a causative relationship, especially considering the presence of possible confounding variables (e.g., types of and adherence to diuretics, changes in treatment pressure, and positioning after the complication).

Conclusion

Patients with a history of heart failure, whether HFpEF or HFrEF, may develop symptoms of pulmonary congestion during or after HBOT. However, they can safely complete HBOT following medical optimization with close attention paid to any clinical or pharmacological changes during treatment. Identifying patients at risk of HF exacerbation, and taking these measures to prevent acute symptoms during treatment, is an important objective of the pre-HBOT medical assessment.

References

- 330 1. Moon R UHMS. Hyperbaric Oxygen Therapy Indications. 14th, ed2019.
- 331 2. Jain KK. Indications, Contraindications, and Complications of HBO Therapy. In: Jain KK, editor.
- Textbook of Hyperbaric Medicine: Springer; 2017. p. 79-84.
- 333 3. Shupak A, Gilbey P. Effects of Pressure. Physiology and Medicine of Hyperbaric Oxygen
- 334 Therapy2008. p. 513-26.
- 4. Heyboer M, 3rd, Wojcik SM, Grant WD, Chambers P, Jennings S, Adcock P. Middle ear
- barotrauma in hyperbaric oxygen therapy. Undersea Hyperb Med. 2014;41(5):393-7.
- 337 5. Heyboer M, 3rd, Sharma D, Santiago W, McCulloch N. Hyperbaric Oxygen Therapy: Side Effects
- 338 Defined and Quantified. Adv Wound Care (New Rochelle). 2017;6(6):210-24.
- 339 6. Weaver LK, Churchill S. Pulmonary edema associated with hyperbaric oxygen therapy. Chest.
- 340 2001;120(4):1407-9.
- 341 7. Mathieu D, Favory R, Collet F, Linke J-C, Wattel F. Physiologic Effects of Hyperbaric Oxygen on
- 342 Hemodynamics and Microcirculation. Handbook on Hyperbaric Medicine: Springer-Verlag; 2006. p. 75-
- 343 101.
- 344 8. Whalen RE, Saltzman HA, Holloway DH, Jr., McIntosh HD, Sieker HO, Brown IW, Jr.
- Cardiovascular and Blood Gas Responses to Hyperbaric Oxygenation. Am J Cardiol. 1965;15(5):638-46.
- 346 9. Pisarello JB CJ, Lambertsen CJ, Gelfand R, editor Human circulatory responses to prolonged
- 347 hyperbaric hyperoxia in Predictive Studies V. Proceedings of the Ninth International Symposium on
- 348 Underwater and Hyperbaric Physiology, Undersea and Hyperbaric Medical Society; 1987.
- 349 10. Pelaia P RM, Conti G, De Blasi RA, Bufi M, Antonelli M, Bortone C. Hemodynamic modifications
- during hyperbaric oxygen therapy. J Hyperb Med. 1992;7(4):229-37.

- 351 11. McMahon TJ, Moon RE, Luschinger BP, Carraway MS, Stone AE, Stolp BW, et al. Nitric oxide in
- 352 the human respiratory cycle. Nat Med. 2002;8(7):711-7.
- 353 12. Weaver LK, Howe S, Snow GL, Deru K. Arterial and pulmonary arterial hemodynamics and
- oxygen delivery/extraction in normal humans exposed to hyperbaric air and oxygen. J Appl Physiol
- 355 (1985). 2009;107(1):336-45.
- 356 13. Nakada T, Koike H, Katayama T, Watanabe H, Yamori Y. Increased adrenal epinephrine and
- 357 norepinephrine in spontaneously hypertensive rats treated with hyperbaric oxygen. Hinyokika kiyo Acta
- 358 urologica Japonica. 1984;30(10):1357-66.
- 359 14. Heyboer Rd M, Wojcik SM, Smith G, Santiago W. Effect of hyperbaric oxygen therapy on blood
- pressure in patients undergoing treatment. Undersea Hyperb Med. 2017;44(2):93-9.
- 361 15. Schiavo S, Djaiani C, DeBacker J, Albertini L, Santa Mina D, Buryk-Iggers S, et al. Magnitude and
- 362 Clinical Predictors of Blood Pressure Changes in Patients Undergoing Hyperbaric Oxygen Therapy: A
- 363 Retrospective Study. Int J Environ Res Public Health. 2020;17(20).
- 364 16. Molenat F, Boussuges A, Grandfond A, Rostain JC, Sainty JM, Robinet C, et al. Haemodynamic
- 365 effects of hyperbaric hyperoxia in healthy volunteers: an echocardiographic and Doppler study. Clin Sci
- 366 (Lond). 2004;106(4):389-95.
- 367 17. Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017
- 368 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart
- 369 Failure. Can J Cardiol. 2017;33(11):1342-433.
- 370 18. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC
- 371 Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J.
- 372 2021;42(36):3599-726.
- 373 19. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal
- definition and classification of heart failure: a report of the Heart Failure Society of America, Heart

- 375 Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing
- 376 Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure.
- 377 2021;23(3):352-80.
- 378 20. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA
- 379 Guideline for the Management of Heart Failure: A Report of the American College of
- 380 Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation.
- 381 2022;145(18):e895-e1032.
- 382 21. Gazewood JD, Turner PL. Heart Failure with Preserved Ejection Fraction: Diagnosis and
- 383 Management. Am Fam Physician. 2017;96(9):582-8.
- 384 22. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology,
- diagnosis, and treatment. Eur Heart J. 2011;32(6):670-9.
- 386 23. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med.
- 387 2004;351(11):1097-105.
- 388 24. Kenmure AC, Murdoch WR, Hutton I, Cameron AJ. Hemodynamic effects of oxygen at 1 and 2
- 389 Ata pressure in healthy subjects. J Appl Physiol. 1972;32(2):223-6.
- 390 25. Leitman M, Efrati S, Fuchs S, Hadanny A, Vered Z. The effect of hyperbaric oxygenation therapy
- on myocardial function. Int J Cardiovasc Imaging. 2020;36(5):833-40.
- 392 26. Li Y, Hao Y, Wang T, Wei L, Wang W, Liang Y, et al. The Effect of Hyperbaric Oxygen Therapy on
- 393 Myocardial Perfusion after the Implantation of Drug-Eluting Stents. Ann Clin Lab Sci. 2018;48(2):158-63.
- 394 27. Aparci M, Kardesoglu E, Suleymanoglu S, Uzun G, Onem Y, Uz O, et al. Hyperbaric oxygen
- therapy improves myocardial diastolic function in diabetic patients. Tohoku J Exp Med. 2008;214(3):281-
- 396 9.
- 397 28. Mak S, Azevedo ER, Liu PP, Newton GE. Effect of hyperoxia on left ventricular function and filling
- pressures in patients with and without congestive heart failure. Chest. 2001;120(2):467-73.

29. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22(3):391-412.

Supporting information

405

- S1 Table. Approved Indications for Hyperbaric Oxygen Therapy in Canada and the United
- 407 States. Hyperbaric oxygen therapy indications approved by Health Canada (*) or the US Food
- and Drug Administration (†). Unlabeled items are approved by both agencies.